<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-65777</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">The 4-5% of the breast cancer patients have metastases in the eye. We present the case of a 30-year-old woman with an infiltrant duct carcinoma of the breast pT2N2M0 HER2 positive. Six months after primary radical treatment she had a systemic relapse with multiples metastaticsites, so several treatment with trastuzumab in combination with chemotherapy were started. After 4 years patient presented multiple white-coloured micronodules in the iris of the right eye. Only a 3-7.8% of ocular metastases are located in the iris. With mantenaince therapy with trastuzumab natural history of the illness has changed. Several studies had analyzed if metastases in the brain during treatment with trastuzumab have increased in comparison with the pretrastuzumab era.The infrequent presentation of metastases in the anterior uveal makes difficult to establish if it is an spontaneous fact or if it is favoured by trastuzumab treatment</dc:description>
<dc:creator>Chirivella González, I</dc:creator>
<dc:creator>Martínez Belda, R</dc:creator>
<dc:creator>Roselló Keranën, S</dc:creator>
<dc:creator>Fons Moreno, A</dc:creator>
<dc:creator>Pérez-Fidalgo, J. A</dc:creator>
<dc:creator>LLuch Hernández, A</dc:creator>
<dc:creator>Villaarteaga, J</dc:creator>
<dc:creator>Bermejo de Lasheras, B</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El 4-5% de las pacientes con cáncer de mama presentan metástasis oculares. Presentamos a una mujer de 30 años con un carcinoma ductal infiltrante de mama pT2N2M0 HER2 positivo. A los seis meses de finalizar el tratamiento presentó una recaída sistémica con múltiples localizaciones metástaticas por lo que inició tratamientos combinados de trastuzumab mantenido y quimioterapia. Tras 4 años con trastuzumab de mantenimiento presenta en iris de ojo derecho multiples micronódulos blanquecinos. Solo un 3-7.8% de las metástasis oculares se localizan en el iris. Con la terapia mantenida con trastuzumab la historia natural de la enfermedad avanzada ha cambiado, diversos estudios analizaron si existe mayor frecuencia de metástasis cerebrales en pacientes tratados con trastuzumab que en la era pretrastuzumab. La infrecuente aparición de metástasis en úvea anterior hace difícil establecer si es un hecho espontáneo o si está favorecido por el tratamiento con trastuzumab</dc:description>
<dc:source>An Med Interna;25(4): 178-180, abr. 2008. ilus</dc:source>
<dc:identifier>ibc-65777</dc:identifier>
<dc:subject>^d1968^s22016</dc:subject>
<dc:subject>^d31593^s22016</dc:subject>
<dc:subject>^d^s22012</dc:subject>
<dc:subject>^d31593^s22067</dc:subject>
<dc:subject>^d28111^s22009</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28111^s22053</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d^s22016</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d974^s22000</dc:subject>
<dc:subject>^d974^s22020</dc:subject>
<dc:subject>^d2320^s22012</dc:subject>
<dc:subject>^d9555^s22016</dc:subject>
<dc:subject>^d1968^s22053</dc:subject>
<dc:subject>^d1968^s22012</dc:subject>
<dc:subject>^d9555^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>200804</dc:date>
</metadata>
</record>
</ibecs-document>
